A recombinant plasmid has been designed to express the gene encoding a type I methotrexate-resistant dihydrofolate reductase, derived from the bacterial plasmid R483, in DHFR" Chinese hamster ovary cells. Vectors containing the wild type gene, whose coding sequence initiates with a GTG codon, fail to direct the synthesis of detectable levels of protein. Substitution of the GTG codon by an ATG codon using in vitro mutagenesis overcomes this block; cells transfected with the modified vector synthesize a functional prokaryotic protein that sustains the growth of these cells in the presence of otherwise lethal levels of methotrexate. Growth of these cells, unlike cells expressing the mammalian form of the enzyme, is dependent upon the presence of dihydrofolic acid in the culture media. This property is consistent with the inability of the type I enzyme to reduce folate to dihydrofolate, and enabled the development of a selection strategy whereby prokaryotic and mammalian DHFRs genes could be used sequentially as independently selectable markers.
INTRODUCTION
Dihydrofolate reductase (DHFR) catalyzes the NADPH-linked reduction of dihydrofolate to tetrahydrofolate, an essential cofactor of purine, thymidine and glycine biosynthesis (1) . A variety of folate analogues, such as methotrexate (MTX) and trimethoprim, have been described that inhibit DHFR activity, which when employed in vivo result in cell death (1, 2) . Overproduction of the enzyme can lead to a drug-resistant phenotype (3, 4) as can the expression of DHFR's having reduced affinities for the substrate inhibitor due to alterations in the hydrophobic substrate binding pocket (5) (6) (7) . In addition, resistance to folate analogues can be obtained by the generation of cells unable to transport the drug into the cell (8) . The use of MTX to select for mammalian cells in culture expressing elevated levels of DHFR has permitted the development of DHFR cDNA transducing vectors capable of efficiently converting DHFR-deficient Chinese hamster ovary (CHO) cells (9) to a DHFR + phenotype (10, 11) . It has proven possible to amplify the transfected sequences in these cells in a fashion similar to the endogenous DHFR gene by selections in increasing levels of MTX (11, 12) ; this has permitted the introduction and expression of a variety of cellular and viral genes of interest by exploiting the ability of transfected sequences to be co-amplified along with the DHFR marker (13) . However, it has proven difficult to utilize the cloned DHFR cDNA as a selectable marker in wild type cells because of competing DHFR resulting from expression of the endogenous gene (13) ; this drawback has been overcome by use of a cDNA encoding a MTX-resistant form of the enzyme (7) .
There exist two types of plasmid-encoded DHFRs in bacteria (14) (15) (16) , distinguished by their extent of resistance to folate analogs (17) . While both types can reduce dihydrofolate to tetrahydrofolate, neither can, in contrast to their mammalian counterparts, reduce folate to dihydrofolate (18, 19) . The type II DHFR is composed of four equal subunits (20, 21) . Highly resistant to trimethoprim, the type II DHFR is structurally distinct from other known DHFRs. The gene encoding the type II DHFR has been reported to transform cultured mouse cells to MTX-resistance (22) , although such transformation occurred only at a low frequency and remains to be confirmed. The type I DHFR, encoded by plasmid R483 (14, 16) and the transposition element TN7 (15) , is a homodimeric enzyme (19) that displays a moderate sensitivity to MTX (17) . Its gene has been cloned and the nucleotide sequence determined (23, 24) . Comparison of the amino acid sequence of a variety of procaryotic and eucaryotic DHFRs with the type I DHFR shows a striking conservation of sequence (24) in a region of the enzyme revealed by X-ray crystallography to represent a hydrophobic binding pocket for the substrate (25, 26) . Since the type I enzyme is structurally related to the mammalian enzyme, yet possesses markedly different metabolic properties, we were interested in determining whether this plasmid-encoded DHFR could be expressed and function in mammalian cells. In this report we demonstrate that type I plasmid-encoded DHFR is active in hamster cells.
MATERIALS AND METHODS

Materials
Dihydrofolate, MTX, and deoxynucleoside triphosphates were purchased from Sigma Chemical Co. Radiolabeled ATP (PB10218) and dCTP (PB10165) were obtained from Amersham Corp. Nitrocellulose was supplied by Schleicher and Schuell. All DNA restriction and modification enzymes utilized were purchased from commercial sources (Bethesda Research Labs, New England Biolabs, or Boehringer-Mannheim) and used according to the manufacturers' recommendations.
Plasmid constructions pEHBall4 is a derivative of pE342 (27, 28) , a Hepatitis B virus surface antigen expression plasmid under the transcriptional control of the SV40 early promoter, in which a unique Hindlll site has been inserted into the surface antigen coding region precisely 225-bp 3' of the HBsAg translational initiation codon. For the construction of pR483-ATG, the 510-bp EcoRI-Hindlll fragment spanning the R483 DHFR was isolated from the M13 replicative forms containing either the altered (ATG) or the wild-type (GTG) initiation codons. These were inserted into EcoRI-Hindlll cleaved pEHBalH between the SV40 early promoter and the Hepatitis B virus sequences. Bacteriophage vectors M13 mplO and mpl 1 (29) were utilized to provide unique restriction sites flanking the R483 insert as well as to provide a template for the mutagenesis of the R483 gene. Plasmid pTMlO, a pBR322-based plasmid containing a 1600-bp insert spanning the type I DHFR derived from the R plasmid R483 has been previously described (24) . DNA Manipulations DNA sequencing was performed by the dideoxynucleotide chain termination method (30) using single-stranded M13 templates (29) . Site-directed mutagenesis (31) using a synthetic 19 base primer (5'-GGAAGAATTATGAACTATC) was performed by hybridizing the primer to purified template for 15' at 55° C in a reaction mixture containing 50mM Tris-HC1, pH 7.5, 50mM NaCl, lOmM MgCl, and 5mM dithiothreitol. After cooling to room temperature, ATP to lmM and 20 units T4 DNA ligase were added. After 2 hr incubation at room temperature, the reaction mixture was used to transform competent JM101. The next day, phage were screened using the method of Benton and Davidson (32) and the filters hybridized as described (33) and were washed twice in 6xSSPE at room temperature and twice in 3M tetramethylammonium chloride. 50mM Tris, pH 8, 2mM EDTA, 0.3% SDS at 53°C (34) . Hybridizing plaques were picked, rescreened and the plaque-purified recombinant phage were sequenced as described above. Cell culture and transfpctions DHFR" deficient Chinese hamster ovary (CHO) K1-DUXB11 cells (9) were propagated as described in Ham's F12 media supplemented with glycine, hypoxanthine, and thymidine (GHT) (7) . Transfection of DHFR* cells was performed using the calcium phosphate coprecipitation technique (35) with a 45 second shock of 20% (vol/vol) glycerol 3 hr after the addition of DNA. Media was replenished and the cells allowed to grow for two days, at which time the cells were trypsinized and passaged into selective media (lacking GHT) supplemented with 7% dialyzed calf serum and dihydrofolic acid. Colonies were either counted after staining with crystal violet or were isolated using glass cloning cylinders (Bellco) 2-3 weeks later. Southern analysis of transfprtpd CHO cells Genomic DNA was isolated from confluent monolayers of transfected cells by phenol extraction of whole cell extracts prepared by dissolving the cells in lOOmM NaCl, lOmM EDTA, 50mM Tris, pH 8, 0.3% SDS and 50 /jg/ml proteinase K. Transfer of DNA from agarose gels to nitrocellulose filters was according to the method of Southern (36) . The DNAs were digested and electrophoresed on 0.7% agarose gels. After denaturation and neutralization, the DNA was transferred to nitrocellulose according to the method of Southern (36) . The filters were then hybridized with 10 7 cpm of 7 32 P-labelled DNA derived from the 490-bp Hpal DHFR fragment. The hybridization was performed in 5xSSPE, 50% formamide, 0.3% SDS, 10% dextran sulfate at 42°C for 12 hours (33). The . This fragment was inserted into M13 mplO to create a template for sitedirected mutagenesis using a synthetic oligonucleotide. The altered nucleotide that converts the GTG triplet to an ATG triplet is also indicated.
filter was washed in 2xSSPE, 0.3% SDS at 42°C and exposed 72 h with an intensifying screen.
Construction of a mammalian expression vector encoding the type 1 DHFR
The gene encoding the type I DHFR is contained within a 490-bp Hpal fragment derived from the E. coli R-plasmid R483 (23, 24) . The nucleotide sequence and deduced amino acid sequence of the type I DHFR is shown in Fig. 1 . From the known aminoterminal sequence of this enzyme (37) it appears that translation of its mRNA initiates at a GUG codon. Efforts to directly express the type I DHFR gene in mammalian cells using the SV40 early promoter were unsuccessful, a failure, we reasoned, reflecting the inability of mammalian ribosomes to initiate protein synthesis at GUG triplets (38) . To address this possibility, we modified the type I DHFR gene by oligonudeotide-directed mutagenesis such that the presumed initiation codon was converted to an ATG. A synthetic 19-mer oligonucleotide containing a single mismatch was used to specifically alter the GTG codon to an ATG codon. Approximately 0.1% of the resulting M13 plaques hybridized at high stringency to the synthetic primer. One such plaque was selected; sequence analysis confirmed that the sequence of the type I DHFR was altered in the desired manner (data not shown). It can be noted (Fig. 1 ) that the converted initiation codon contains flanking purine nucleotides at positions -3 and +4, a configuration thought to promote the efficient use of AUG triplets as initiation codons in mammalian cells (38, 39) .
The use of M13mpll as a cloning vehicle for the DNA fragment encoding the type 1 DHFR positioned an EcoRl site at the 5' end of the gene and a Hindlll site following the restored termination codon (GTT/GATCC). We inserted the EcoRI-Hindlll fragments of both the original (GTG) and altered (ATG) M13 replicative forms into an expression vector (pEHBalH) that contained unique EcoRl and Hindlll sites in the proper orientation. pEHBall4 is derived from plasmid p342E (27, 28) , which uses an SV40 early promoter to efficiently transcribe the gene encoding the surface antigen of Hepatitis B virus. The gene encoding the modified type I enzyme was inserted between the corresponding sites of the vector to create plasmid pR483-ATG (Fig. 2) . In a similar fashion, the unmodified type I gene was inserted into the expression vector to create pR483-GTG, a control construction which differs from pR483-ATG by the single nucleotide change in the presumed initiation codon. The type I DHFR sequences were followed by HBsAg sequences that provide signals for the polyadenylation of the chimeric transcript (40) . Expression of the typp I gene in CHO cells were transfected using the calcium phosphate precipitation technique with 2.5 ^g plasmid DNA each. Two days after transfection, cells were trypsinized and passaged into selective media (Ham's F12 lacking hypoxanthine, thymidine, and glycine) supplemented with 7% serum, 6 jiM dihydrofolate and the indicated level of MTX. Two weeks later, cells were stained with crystal violet and colonies counted. pFDll, murine DHFR expression plasmid; pFR400, methotrexate resistant murine DHFR expression plasmid; pR483-ATG, R483 expression vector having ATG initiation codon; pR483-GTG, R483 expression vector having bacterial (GTG) initiation codon.
instead p-aminobenzoate is metabolized to form dihydrofolate directly (1). To determine if functional type I DHFR can be expressed in mammalian cells, we transfected pR483-ATG and pR483-GTG plasmids into a DHFR-deficient CHO cell line (9), selecting for the emergence of cells capable of reducing exogenously supplied dihydrofolate. As a positive control, we also transfected separate cultures with pFDll and pFR400, plasmids encoding a wild-type and a MTX-resistant murine DHFR, respectively; both can convert DHFR' cells to a DHFR + phenotype (7).
As shown in Table 1 , plasmid pR483-ATG, but not pR483-GTG, was capable of transforming DHFR" CHO cells to a DHFR + phenotype, establishing that the type 1 enzyme is capable of functioning within mammalian cells. Addition of the folate analogue MTX prevented the formation of DHFR + colonies from cells transfected with pFDll (which encodes a wild-type murine DHFR), but had marginal effect on colony outgrowth on cells transfected with pFR400 (which encodes a MTX-resistant form of the enzyme). As expected, MTX had no significant effect on the number of DHFR + colonies generated upon transfection of cells with pR483-ATG.
Methotrexate growth inhibition
The results shown in Table 1 suggested that the ability of the Type 1 DHFR to transform DHFR' cells to a DHFR + phenotype was virtually unaffected by the addition of up to lOOOnM MTX. To more accurately determine the extent to which the type 1 DHFR protected cells against the growth inhibitory effects of MTX, two DHFR + clones resulting Dihydrofolate arid dpppndenre of rells expressing the type I DHFR It has been reported that the plasmid-encoded type I DHFR is unable to reduce folate to dihydrofolate (18, 19) ; as such, we explored the requirement for this precursor 
Southern analysis of transfertpri THO cells
To verify that vector sequences were indeed present within the genome of cells transfected with type I DHFR expression plasmid, DNA from R483 DHFR + cells was analyzed using the method of Southern (36) . High molecular weight DNA was isolated from two independent DHFR + cell lines that arose after transfection of DHFR' cells. The DNAs were digested with Bglll, which does not cleave pR483-ATG, and with EcoRl and Hindlll, which each cleave the plasmid once at opposing ends of the type I DHFR gene. The DNAs were analyzed by blot hybridization with a probe specific for the type I DHFR sequences. As shown in Fig. 5 , both cell lines showed a single, faintly hybridizing Bgill fragment (lanes C, F, 1), demonstrating that the type 1 DHFR had integrated into chromosomal DNA. The Hindlll and EcoRl digested DNAs gave rise to three bands: an intensely labeled band at 5 kb, a size identical to linearized pR483-ATG, and two less intensely labeled fragments. No significant difference was noted between DNA isolated from two different DHFR + cell clones transfected with pR483-ATG DNA. The pattern of hybridization also suggested that the transfected plasmid had integrated at no more than two sites in both the CHO-R483-1 (lanes A-C) and CHO-R483-2 (lanes D-F) cell lines, with at least one site containing a linear concatamer of plasmid DNA. The total number of copies of introduced sequences is approximately 5 for the CHO-R483-1 cell line and 15 for the CHO-R483-2 cell line, based upon comparison to EcoRI-cleaved plasmid DNA electrophoresed and blotted onto the same filter (lanes G and H). The less intensely hybridizing bands, whose sizes are specific to particular cell clones, presumably reflect the junction frag- DHFR-CHO cells expressing the Type IDHFR were transfected in quadruplicate with the indicated DHFR plasmids and selected as described in Table 1 in the absence of dihydrofolate supplementation. Two weeks after plating into selective media, the plates were stained with crystal violet and colonies counted.
cells were either mock-transfected or were transfected again with the pR483-ATG plasmid (Table 2) . However, large numbers of colonies appeared when either pFDll or pFR400 was used, establishing the feasibility of independently selecting cells by sequential transfections with vectors encoding prokarytic and mammalian DHFRs.
DISCUSSION
The ability to transfer cloned genes into cultured mammalian cells has provided an opportunity to study gene expression in a defined cellular background. Selectable markers, such as thymidine kinase, hypoxanthine phosphoribosyltransferase, adenine phosphoribosyltransferase and murine dihydrofolate reductase, have been used with great success to facilitate gene transfer into recipient cells lacking the marker gene (for review see 13) . The recent development of dominant selectable markers including the bacterial genes xanthine-guanine phosphoribosyl transferase and aminoglycoside 3' phosphotransferase as well as a vector based upon an altered murine dihydrofolate reductase isolated from a MTX-resistant 3T6 cell line (13) now permits the introduction of genes into a wide variety of mammalian tissue culture cells. The conversion of the gene encoding the trimethoprim-resistant R483 DHFR to a form recognizable by mammalian cells now provides an additional selectable marker for tissue culture cells. Our findings that cells expressing this form of DHFR are dependent upon exogenously supplied DHF is consistent with the known inability of the type I enzyme to reduce folate to dihydrofolate, and enabled the development of a selection strategy based on the successive introduction of the prokaryotic and mammalian versions of DHFR genes.
Although we had originally suspected that the gene encoding the R483 DHFR could be amplified by MTX treatment, we have found that cells containing only 5-15 copies of the pR483-ATG plasmid are able to grow in 100 uM MTX, which may limit the use of MTX in achieving a reasonable level of gene amplification. Although this was not expected in light of findings that this enzyme displays an intermediate sensitivity to MTX in vitro (17) , it may reflect to some extent the protective effect of the exogenously supplied DHF. We have noted, for instance, that as the concentration of added DHF is increased when cells undergo MTX selection, the cells tolerate greater concentrations of MTX (data not shown). It may thus still prove possible to amplify the pR483-ATG sequences by treatment with MTX, but perhaps only in the presence of limiting levels of DHF.
The data shown in Table I show that it is possible to select for growth of CHO cells expressing the R483 DHFR in levels of MTX sufficient to inhibit the growth of virtually all mammalian cells. We have attempted to determine if the pR483-ATG vector might be useful as a dominant-acting selectable marker when expressed in other cell lines. We have been able to obtain colonies of both BHK and L cells in the presence of 1 iM MTX and l^M DHF following their transfection with pR483-ATG (data not shown).
Expression of the type I DHFR, as demonstrated by the conversion of DHFR-deficient CHO cells to a DHFR + phenotype, was achieved only after conversion of the GTG initiation codon to an ATG. This result is consistent with the proposal that mammalian cells, contrary to bacteria, are unable to efficiently recognize GUG as an alternative translational initiation codon; additionally, it more firmly localizes this triplet as the "natural" translational initiation site of the gene. Recent studies have demonstrated that "synthetic" AUG codons can effectively promote translational initiation in mammalian cells (28, 38, 41) . Based on these observations, it seems reasonable to expect that pR483-GTG might direct the synthesis of a polypeptide similar to the type I DHFR, lacking only the five amino terminal residues of the enzyme, if translation could initiate at the in-frame AUG codon located 15 nucleotides 3' of the initiation GUG. However, we have never observed phenotypically DHFR + cells resulting from a transfection with pR483-GTG, raising the possibility that the N-terminal five amino acids may be essential for enzyme activity. Alternatively, it can be argued that this in-frame AUG triplet is in a configuration unsuitable for efficient translation initiation, a proposal consistent with indications that AUG's lacking a purine nucleotide at the -3 position are poorly utilized as translational initiations codons in mammalian cells (38) . The clarification of this issue awaits further studies.
